Peptide

CJC-1295

CJC-1295

Evidence TierCWADA PROHIBITED

tuneTypical Dose

30-120 mcg/kg

watchEffect Window

Endocrine biomarker effects within days. Durability limited by current protocol duration.

lockCompliance

WADA PROHIBITED

Overview

Clinical Summary

CJC-1295 is a long-acting GHRH analog peptide that increases endogenous growth hormone release. It is used for growth hormone and IGF-1 elevation claims, mainly in research contexts.

Human studies show increased growth hormone and IGF-1 levels, which supported investigation for endocrine indications. Controlled evidence for improved body composition, strength, or recovery in healthy users is limited. Minority claims include improved sleep quality through growth hormone physiology, but outcomes data are sparse. Even phase I studies reported injection-site reactions and systemic vasodilatory symptoms, so the safety story is not as clean as marketing usually implies.

Long-acting GHRH analog designed to prolong GH-releasing activity and increase IGF-1.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • GH/IGF-1 axis activation

Secondary Outcomes

  • GH pulsatility preservation
  • Serum biomarker changes

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy
  • Lactation
  • Active cardiac disease
  • Endocrine instability
  • Active malignancy

Side effects

  • Injection site reactions
  • Flushing
  • Headache
  • Water retention

Interactions

  • Concurrent GH-axis peptides/secretagogues
  • Unverified hormone-active supplements

Avoid if

  • Unsupervised use
  • Competitive athlete without compliance review
  • Cardiac disease
  • Unknown compounding quality

Evidence

Study-level References

cjc-1295-SRC-001Randomized, placebo-controlled, double-blind ascending-dose trial.
Sourceopen_in_new

Teichman et al. 2006. “Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. DOI: 10.1210/jc.2005-1536; PMID: 16352683. URL: https://pubmed.ncbi.nlm.nih.gov/16352683/

Population: Healthy adults, ages 21–61.

Dose protocol: 30, 60, 90, 120 mcg/kg, single doses and 2-3 weekly/biweekly doses over 28-49 days.

Key findings: Dose-dependent increases in GH (2-10 fold, ~6+ days) and IGF-1 (1.5-3 fold, 9-11 days). Estimated half-life 5.8-8.1 days. IGF-1 stayed above baseline up to ~28 days after multiple doses. Injection-site and vasodilatory adverse effects were reported even in early studies.

Notes: Strong endocrine biomarker signal. Does not establish long-term performance or body-composition outcomes.

Paper content

Dose-dependent increases in GH (2–10 fold, ~6+ days) and IGF-1 (1.5–3 fold, 9–11 days); estimated half-life 5.8–8.1 days; IGF-1 stayed above baseline up to ~28 days after multiple doses; no serious adverse reactions reported in abstracted summary.

cjc-1295-SRC-002Physiologic endocrine trial with endocrine monitoring.
Sourceopen_in_new

Ionescu & Frohman 2006. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. DOI: 10.1210/jc.2006-1702; PMID: 17018654. URL: https://pubmed.ncbi.nlm.nih.gov/17018654/

Population: Healthy men 20–40 years.

Dose protocol: 60 or 90 mcg/kg SC, one dose, 1-week follow-up endocrine sampling.

Key findings: GH secretion increased with preserved pulsatility. Trough GH rose substantially and mean GH/IGF-1 increased.

Notes: Supports mechanism plausibility and pulse-preservation question. No robust clinical endpoint claims.

Paper content

GH secretion increased with preserved pulsatility; trough GH rose substantially and mean GH/IGF-1 increased.

cjc-1295-SRC-004Registered phase 2 randomized, placebo-controlled, double-blind trial.
Sourceopen_in_new

ClinicalTrials.gov NCT00267527, “A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity.”

Population: HIV patients with visceral obesity.

Dose protocol: Low/high CJC-1295 arms with weekly escalation (registry context) over 12-week treatment period, 6-week follow-up.

Key findings: Trial record indicates completion/registration details. Public outcome results were not present in the accessible registry summary used for this review.

Notes: Useful for protocol scope and context, weak on outcome publication transparency.

Paper content

Trial record indicates completion/registration details; public outcome results were not present in the accessible registry summary used for this review.

cjc-1295-SRC-005Contemporary phase-II reporting in HIV population context.
Sourceopen_in_new

Aidsmap, July 2006. “Lipodystrophy study halted after patient death.”

Population: HIV-related visceral obesity trial participants.

Dose protocol: Reported escalating low-dose arm 60/90/120 mcg/kg and high-dose arm 60/120/240 mcg/kg, one-time interruption context.

Key findings: Phase II trial interruption reported during operations. Causality around one participant death was unconfirmed in source.

Notes: Historical safety and governance signal. Not a peer-reviewed outcome trial report.

Paper content

Phase II trial interruption reported during operations; causality around one participant death was unconfirmed in source.

cjc-1295-SRC-006Regulatory safety compounding guidance table.
Sourceopen_in_new

FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.”

Population: U.S. compounding context for human use.

Dose protocol: N/A

Key findings: FDA flagged CJC-1295 for potential immunogenicity/impurity complexity and noted serious adverse events (e.g., increased heart rate and systemic vasodilatory reaction), with limited available clinical data.

Notes: This source is regulatory risk-oriented, not a clinical efficacy source.

Paper content

FDA flagged CJC-1295 for potential immunogenicity/impurity complexity and noted serious adverse events (e.g., increased heart rate and systemic vasodilatory reaction), with limited available clinical data.

cjc-1295-SRC-007Regulatory classification list.
Sourceopen_in_new

WADA, Prohibited List (“What is Prohibited,” section S2.2.4 growth hormone-releasing factors).

Population: Competitive athletes.

Dose protocol: N/A

Key findings: CJC-1295 is listed as a growth hormone-releasing factor example in S2.2.4.

Notes: Critical for anti-doping compliance logic and product suitability.

Paper content

CJC-1295 is listed as a growth hormone-releasing factor example in S2.2.4.

Guides

Setup

Help